Johnson & Johnson (NYSE:JNJ) is reportedly considering selling its stroke care unit, Cerenovus, in a deal that could value ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

U.S. pharmaceutical company Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for at least $1 billion U.S. The sale is part of Johnson & Johnson’s ongoing efforts ...

Johnson & Johnson is looking to sell its Cerenovus stroke therapy business, according three unnamed people "with knowledge of ...

Johnson & Johnson aims to streamline operations by selling its stroke care business, Cerenovus, valued at $1B+.

Johnson & Johnson has put its stroke care business up for sale, aiming for a valuation of more than $1bn, as part of its ...

Johnson & Johnson MedTech (NYSE: JNJ) announced today that it launched the CereGlide 92 catheter system for treating acute ...

Johnson & Johnson (NYSE:JNJ), the New Jersey-based healthcare company, is planning to sell its stroke care business, ...

A second trial of a clot evacuation approach to remove a hematoma in spontaneous ICH has shown some encouraging results, despite a neutral primary endpoint.

LOS ANGELES -- For patients with large vessel occlusion (LVO) strokes, researchers found ways to make adjunctive ...

MIND was a prospective, open-label trial that enrolled adults up to 80 years old with moderate-large (20-80 mL) ...